Etherna

Pioneering mRNA-LNP platforms for innovative drug delivery solutions

Ghent, Belgium · Founded 2013 · $103.8M raised

Headquarters
Ghent
Employees
11–50
Founded
2013
Business Model
B2B
Website
etherna.be
Total Funding
$103.8M
Last Round
$39.0M Series BAug 2022
Rounds
3

About

Etherna (formerly eTheRNA immunotherapies) is a clinical-stage nucleic acid medicine company founded in 2013 as a spin-off of Vrije Universiteit Brussel (VUB), based in Belgium. The company has more than 20 years of combined academic and biotech expertise in mRNA and lipid nanoparticle (LNP) technology, and operates as a technology platform business partnering with pharmaceutical and biotech companies on custom mRNA design, LNP formulation, and GMP-grade RNA production services. Etherna's proprietary delivery platforms enable tailored and innovative solutions for mRNA-based therapeutics, vaccines, and immunotherapies.

Summary

Etherna is a Biotech company based in Ghent, Belgium, founded in 2013. It has raised $103.8M in total across 3 rounds, most recently a $39.0M Series B round in Aug 2022. Investors include Kenneth Chien / Novalis LifeSciences, PMV and Boehringer Ingelheim Venture Fund.

Tech & App Stack

8 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series BSeries BAug 2022
$39.0M

Sign up to see all 3 rounds

Series A through Series B — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Etherna on Indexed.vc
<a href="https://indexed.vc/companies/etherna"><img src="https://indexed.vc/api/badge/company/etherna" alt="Etherna on Indexed.vc" width="260" height="76" /></a>